The UK Government’s Innovate has invested over €78.5M into a new Cell-therapy manufacturing facility for the major UK biotech Catapult Cell Therapy to be located in the growing Biotech cluster in Stevenage.
Catapult is a big deal in the UK Biotech scene (apparently) and their division in Cell therapeutics founded in 2012 already has a lot of UK governmental support. Indeed, their facilities on the 12th floor of the Guy’s & St Thomas’ Hospital (one of the key UK Biomedical research centres) in London, includes a National Institute for Health Research (NIHR) lab as well as a clinical research facility, and they are part of the prestigious Academic Health Sciences Centre King’s Health Partnerhip ‘Belt’.
Now, having chosen the Stevenage Biosciences Catalyst Campus as the site for their new £55M Manufacturing facility, Catapult are hoping to expand the Cell-therapy industry within the UK. Completion is expected by 2017, with projected commercialization of products from the facility to generate £1.2Bn by 2020 (80% of which will be through export).